Kay Joseph D, Chan Kak-Chen
Division of Cardiology, University of Colorado, Denver, Colo., USA.
Congenit Heart Dis. 2008 May-Jun;3(3):209-12. doi: 10.1111/j.1747-0803.2008.00178.x.
Percutaneous stenting of both native and recurrent coarctation of the aorta has become an acceptable alternative to surgical repair in most centers throughout the world. Severe complications such as aortic rupture, dissection, and late pseudo aneurysm formation are rare but worrisome complications. In many countries, commercially available balloon expandable covered stents designed for intravascular use are used either for primary stenting, or in treating complications once identified. These endovascular stents, however, are not available in the United States. We report the use of a commercially available covered stent, which has been approved by the Food and Drug Administration for tracheal use, to exclude an aortic pseudo aneurysm that was identified late after stenting a native coarctation.
在世界上大多数中心,经皮主动脉原位缩窄和复发性缩窄支架置入术已成为手术修复的可接受替代方案。诸如主动脉破裂、夹层和晚期假性动脉瘤形成等严重并发症虽罕见但令人担忧。在许多国家,设计用于血管内使用的市售球囊可扩张覆膜支架用于初次支架置入或一旦发现并发症时进行治疗。然而,这些血管内支架在美国无法获得。我们报告了使用一种已获美国食品药品监督管理局批准用于气管的市售覆膜支架,来排除在对原位主动脉缩窄进行支架置入术后晚期发现的主动脉假性动脉瘤。